Discerning the Mauve Factor, Part 1

Woody R. McGinnis, MD, Tapan Audhya, PhD, William J. Walsh, PhD; James A. Jackson, PhD; John McLaren-Howard, DSc, FACN; Allen Lewis, MD; Peter H. Lauda, MD; Douglas M. Bibus, PhD; Frances Jurnak, PhD; Roman Lietha, MD; Abram Hoffer, MD, PhD

Here is an excerpt from the paper:

“Mauve Factor,” or “Mauve” (mov) for brevity, first was detected in the urine of psychiatric patients by the Hoffer group in 1958 and named for its appearance on paper chromatograms.

Irvine extracted the compound from urine, correctly assigned the structure to the pyrrole family, and conferred the common name.  Early technology permitted only qualitative assay.

Hoffer observed that recovery from acute schizophrenia associated with disappearance of Mauve from the urine, regression with reappearance.  Large doses of vitamin B3 suppressed Mauve in schizophrenics.  Pfeiffer reported superior clinical results with combined vitamin B6 and zinc, which suppressed Mauve and improved symptoms in many neurobehavioral disorders.

The Pfeiffer group introduced a colorimetric quantitative assay for Mauve, which utilizes kryptopyrrole (KP) as standard. Structural similarity affords the use of KP as standard for HPL assay, but the 2 molecules are distinct. Mauve was identified mistakenly as KP by Irvine in a high-profile scientific journal in 1969 and again by Sohler in 1970.  A flurry of research on the experimental effects of KP eventuated.  Improved technology demonstrated that KP is not found in human urine, and Mauve was identified indisputably by synthesis as HPL.

To read the entire article, please download the attached PDF.

Attachments:
Download this file (Discerning Mauve Factor Galley Feb 2008.pdf)Mauve Factor[ ]2094 kB

Search